Literature DB >> 12237820

Simple assay for antitumour immunoactive glycoprotein derived from Chlorella vulgaris strain CK22 using ELISA.

Kiyoshi Noda1, Kuniaki Tanaka, Akira Yamada, Jyunko Ogata, Hiroyuki Tanaka, Yukihiro Shoyama.   

Abstract

A quantitative ELISA system was developed using a monoclonal antibody (MAb) specific for an antitumour immunoactive glycoprotein (CVS) derived from C. vulgaris strain CK22. The full measuring range of the assay extends from 0.63 to 10.0 ng/mL of CVS. Although no cross-reaction was observed to proteins tested or other biological response modifiers (BRMs) derived from different sources, cross-reactions were found with culture supernatants from two other strains of C. vulgaris having a strong antitumour immunoactivity. Treatment of CVS with protease, acid or alkali weakened or completely eliminated the reactivity against the MAb and also its antitumour immunoactivities. This ELISA system is suitable for the biologically active form of CVS derived from C. vulgaris strain CK22 and related immunoactive strains. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237820     DOI: 10.1002/ptr.1021

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  3 in total

1.  Purification and characterization of a novel haemagglutinin from Chlorella pyrenoidosa.

Authors:  Chun-Yao Chu; Rang Huang; Liang-Ping Ling
Journal:  J Ind Microbiol Biotechnol       Date:  2006-06-15       Impact factor: 3.346

Review 2.  Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective.

Authors:  Pragya Misra; Shailza Singh
Journal:  Cancer Med       Date:  2019-04-17       Impact factor: 4.452

3.  Cytotoxic effect of clerosterol isolated from Codium fragile on A2058 human melanoma cells.

Authors:  Areum Daseul Kim; Youngki Lee; Sang-Hyuck Kang; Gi Young Kim; Hye Sun Kim; Jin Won Hyun
Journal:  Mar Drugs       Date:  2013-02-06       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.